2-二甲基胺嘧啶-5-硼酸-2,3-二甲基丁二醇酯 | 1032759-30-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-二甲基胺嘧啶-5-硼酸-2,3-二甲基丁二醇酯
• 中文别名: 2-二甲基氨基嘧啶-5-硼酸频那醇酯；2-(二甲基氨基)嘧啶-5-硼酸频那醇酯；2-二甲基氨基嘧啶-5-硼酸频哪醇酯
• 英文名称: N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine
• 英文别名: 2-(dimethylamino)pyrimidine-5-boronic acid pinacol ester
• CAS: 1032759-30-0
• 化学式: C₁₂H₂₀BN₃O₂
• mdl: MFCD07368238
• 分子量: 249.121
• InChiKey: RMPRVJCNMPFBCX-UHFFFAOYSA-N

物化性质

• 熔点：
  107-112℃
• 沸点：
  369.2±34.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  47.5
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Dimethylamino-pyrimidine-5-boronic acid pinacol ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Dimethylamino-pyrimidine-5-boronic acid pinacol ester
CAS number: 1032759-30-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C12H20BN3O2
Molecular weight: 249.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-二甲基胺嘧啶-5-硼酸-2,3-二甲基丁二醇酯 在 N,N-二甲基乙酰胺 、 Cu(OTf)2(py)4 作用下， 以 乙腈 为溶剂， 反应 0.33h， 生成 5-[18F]fluoro-N,N-dimethylpyrimidin-2-amine
  参考文献：
  名称：

  消除杂环正电子发射断层扫描放射性配体的铜介导的 18F-氟化

  摘要：

  用氟 18 (18F) 标记的分子用于正电子发射断层扫描，以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展，但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法，使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究，该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率，以及超过 50 种（杂）芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。

  DOI：

  10.1021/jacs.7b03131
• 作为产物：
  描述：

  5-溴-2-(二甲基氨基)嘧啶 、 联硼酸频那醇酯 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 、 乙二醇二甲醚 为溶剂， 反应 0.25h， 以60%的产率得到2-二甲基胺嘧啶-5-硼酸-2,3-二甲基丁二醇酯
  参考文献：
  名称：

  [EN] PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS
  [FR] INHIBITEURS DE PHOSPHOTIDYLINOSITOL 3-KINASES

  摘要：

  这份披露涉及磷脂酰肌醇3-激酶（PI3Ks）抑制剂，如N-(5-(咪唑并[1,2-a]吡啶-6-基)吡啶-3-基)磺胺衍生物及其相关用途。在某些实施方式中，该披露涉及治疗PI3K相关疾病或症状的方法，包括向需要的受试者施用本文披露的化合物的有效量。在某些实施方式中，受试者可能处于患癌症或血液恶性肿瘤的风险中，表现出症状，正在遭受痛苦，或已被诊断出患有这些疾病。

  公开号：

  WO2017197151A1

文献信息

• [EN] BIARYL SPIROAMINOOXAZOLINE ANALOGUES AS ALPHA2C ADRENERGIC RECEPTOR MODULATORS<br/>[FR] ANALOGUES DE BIARYL-SPIROAMINOOXAZOLINE EN TANT QUE MODULATEURS DE RÉCEPTEUR ADRÉNERGIQUE ALPHA2C
  申请人：SCHERING CORP

  公开号：WO2010042473A1

  公开（公告）日：2010-04-15

  In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的双芳基螺氨氧杂萘类衍生物，作为α2C肾上腺素受体激动剂的调节剂，提供了制备这类化合物的方法，包含一个或多个这类化合物的药物组合物，制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与α2C肾上腺素受体相关的一个或多个条件的方法。
• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE EZH2 ET LEURS UTILISATIONS
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2015110999A1

  公开（公告）日：2015-07-30

  The present invention provides compound of formula 1, or an isotopic form, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, S-oxide or N-oxide thereof. The invention also relates toprocesses for their preparation, to pharmaceutical compositions containing them and use of the compound of formula 1, in the treatment of diseases or disorders mediated by EZH2 (enhancer of zeste homolog 2), particularly cancer.

  本发明提供了式1的化合物，或其同位素形式、立体异构体、互变异构体、药学上可接受的盐、溶剂合物、多晶形态、前药、其S-氧化物或N-氧化物。该发明还涉及它们的制备方法，含有它们的药物组合物以及利用式1的化合物治疗由EZH2（增强子齐斯特同源物2）介导的疾病或紊乱。
• [EN] SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS<br/>[FR] BENZAZINONES SUBSTITUÉS À UTILISER EN TANT QUE COMPOSÉS ANTIBACTÉRIENS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017098440A1

  公开（公告）日：2017-06-15

  The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

  该发明涉及Formula (1A)的LpxC抗菌化合物，其相应的药学上可接受的盐，相应的药物组合物，化合物制备，细菌感染的治疗方法和用途，特别是由革兰氏阴性细菌引起的感染。
• N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS
  申请人：Li Yun-Long

  公开号：US20120157430A1

  公开（公告）日：2012-06-21

  The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

  本发明提供了调节磷脂酰肌醇3-激酶（PI3Ks）活性并且在治疗与PI3Ks活性相关的疾病方面有用的N-(1-(取代苯基)乙基)-9H-嘌呤-6-胺衍生物，例如炎症性疾病、免疫性疾病、癌症和其他疾病。
• 1‐Indanone and 1,3‐indandione Derivatives as Ligands for Misfolded α‐Synuclein Aggregates
  作者：Xianwei Sun、Prasad Admane、Zbigniew A. Starosolski、Jason L. Eriksen、Ananth V. Annapragada、Eric A. Tanifum

  DOI：10.1002/cmdc.202100611

  日期：2022.1.19

  Homing in on the ideal α-synuclein ligand! The effective diagnosis of specific neurodegenerative disorders is complicated by the accumulation of multiple misfolded amyloid species in their pathogenesis. High-affinity and selective probes toward specific amyloid aggregates are imperative. SAR studies on some existing α-synuclein ligands have resulted in leads with high affinity and selectivity toward

  瞄准理想的 α-突触核蛋白配体！特定神经退行性疾病的有效诊断由于其发病机制中多种错误折叠的淀粉样蛋白的积累而变得复杂。针对特定淀粉样蛋白聚集体的高亲和力和选择性探针是必要的。对一些现有 α-突触核蛋白配体的 SAR 研究已发现对 α-syn 相对于 Aβ 和 tau 聚集体具有高亲和力和选择性的先导化合物。